Literature DB >> 3981499

Plasma and synovial fluid gentisate in patients receiving salicylate therapy.

L G Cleland, P J Lowthian, D Imhoff, F Bochner, W H Betts, J O'Callaghan.   

Abstract

Our study was undertaken to assay gentisate, an oxidation metabolite of salicylate, in plasma and synovial fluid (SF) samples from patients taking antiinflammatory doses of aspirin. A close correlation between plasma and SF concentrations was found for (1) salicylate, (2) salicylurate, and (3) gentisate, in 20 patients studied. Our data suggest ready equilibration of these compounds between the plasma and synovial spaces. In vitro experiments confirmed that in the presence of an oxy radical flux, salicylate is oxidized to gentisate. However, no evidence was obtained to implicate peripheral conversion of salicylate to gentisate in inflamed joints where oxy radicals may be produced.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3981499

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

2.  Hydroxyl radical generation by rheumatoid blood and knee joint synovial fluid.

Authors:  H Kaur; S E Edmonds; D R Blake; B Halliwell
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

3.  Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo. Identification of hydroxylated derivatives of salicylate in human body fluids.

Authors:  M Grootveld; B Halliwell
Journal:  Biochem J       Date:  1986-07-15       Impact factor: 3.857

4.  Quantitation of the hydroxyl radical adducts of salicylic acid by micellar electrokinetic capillary chromatography: oxidizing species formed by a Fenton reaction.

Authors:  M Tomita; T Okuyama; S Watanabe; H Watanabe
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.